At the opening of the 37th General Assembly of the West African Post-Graduate College of Pharmacists (WAPCP), Dr. Luke Bawo, Managing Director of the Liberia Medicines and Health Products Regulatory Authority (LMHRA), presented a significant statement addressing the challenges facing the pharmaceutical sector currently.
The assembly, held from April 7-10, 2025, gathered stakeholders from across West Africa to discuss pressing issues related to public health and the pharmaceutical industry.
In his remarks, Dr. Bawo pointed out several critical obstacles, such as the rising costs of medications and the access barriers they create.
He stressed the need for collaborative policies and innovative strategies to keep life-saving drugs affordable and accessible, especially for vulnerable populations.
“This year’s conference theme: “Emerging Substances of Abuse: Implications for the West African Region,” closely aligns with LMHRA’s mission to enhance regulatory frameworks and best practices in pharmacy. The authority is ready to engage in meaningful discussions that will help us better serve communities, navigate drug regulation complexities and improve public health throughout the region,” Dr. Bawo said.
He also addressed the urgent need to combat Antimicrobial Resistance (AMR), which he described as a significant threat to global health.
Dr. Bawo then urged stakeholders to prioritize AMR in their discussions, promoting responsible management of current antibiotics and the development of new treatments.
Furthermore, he pointed out challenges arising from strict regulatory requirements set by various health authorities, advocating for the harmonization of regulations across West African nations.
According to a release, this would streamline processes while maintaining safety and efficacy standards.
Bawo noted that ongoing disruptions in global supply chains, exacerbated by recent health crises, require resilient strategies to ensure a steady supply of essential medicines.
The lasting impacts of public health crises, particularly those from the COVID-19 pandemic, were also key points in Dr. Bawo’s speech.
He called for preparedness strategies that address not only current issues, but also anticipate future public health emergencies.
Regarding ethical considerations, he emphasized the need for increased transparency in drug pricing and clinical trials, highlighting the importance of public trust through accountability and ethical practices in the pharmaceutical sector.
In light of the rising influence of digital advancements, Dr. Bawo underscored the importance of digital transformation within the industry.
He meanwhile, encouraged stakeholders to adopt innovative data management practices that would improve drug development and distribution while ensuring patient safety.
Awesome https://is.gd/tpjNyL